RESUMO
BACKGROUND: Iron deficiency anaemia is the most common nutritional deficiency disorder in the world. Iron deficiency is a potential complication in repeated apheresis donation. The present study was aimed to evaluate serum iron stores in regular plateletpheresis donors. MATERIALS AND METHODS: A total of 60 donors were included in this study, which included 30 regular plateletpheresis donors as cases and controls were 30 first time donors. The donor samples were collected before donation for complete hemogram, transfusion transmissible infections screening and serum iron, total iron binding capacity, percentage saturation of transferrin and serum ferritin. RESULTS: Out of 60 donors, more than half of the donors (56.6 %) had serum ferritin less than 30 ng/mL. Out of these 34 donors, 25 were from the case group and 9 donors in the control group. The median serum ferritin level in cases and controls was 11.86 ng/mL (Interquartile range 4.18-17.34 ng/mL) and 37.92 ng/mL (Interquartile range 27.87-86.20 ng/mL) respectively (p < 0.001). The mean serum iron in cases and controls was 71.23 ± 31.32 µg/dL and 93.53 ± 33.53 µg/dL respectively (p = 0.016). The mean percentage saturation in cases and controls was 20.09 ± 9.31 % and 26.26 ± 9.03 % respectively (p = 0.012). A significant decline in mean serum ferritin with increase in number of annual donations and decrease in donation interval was observed. DISCUSSION: Regular plateletpheresis donation may lead to depletion of iron stores and subclinical iron deficiency. Donors with high platelet count are more likely to exhibit iron deficiency. Periodic serum ferritin estimation in donors participating in regular plateletpheresis donation is warranted.
Assuntos
Doadores de Sangue/estatística & dados numéricos , Deficiências de Ferro/etiologia , Ferro/sangue , Plaquetoferese/métodos , Adolescente , Adulto , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Estudos Prospectivos , Adulto JovemRESUMO
BACKGROUND: This study aims to determine the phlebotomy and procedural outcomes using a vein assessment tool (VAT) in Double Dose Platelet (DDP) collections by apheresis. METHODS: VAT was based on assessing vein visibility, palpation and size with maximum score of 12 and the least being 0 and the scores were graded as adequate and inadequate. A vein-viewer was used for studying cubital vein patterns (type 1-5). Phlebotomy outcome was defined based on need for re-puncture. Procedural outcomes in terms of target yield attained and RBC reinfusion completed. Chi square test and Mann- Whitney U test were used to assess the vein score and pattern against phlebotomy and procedural outcome. RESULTS: Out of 200 DDP collections, the phlebotomy was successful in 88 % with good procedural outcome in 94 % donations. The cut off in VAT scores for successful phlebotomy was ≥8 (AUC: 70 %). Median vein scores of the arm selected for phlebotomy was 9 and graded adequate in 154 (77 %) donations.Odds for successful phlebotomy was 3.7 times higher when donors had an adequate VAT grades(p = 0.003). Procedural outcomes was favourable when at least one arm had adequate VAT grade when compared to both arms being inadequate (98 % vs 82 %; p < 0.001). Phlebotomy failure was more with first time apheresis donors than repeat apheresis donors (p = 0.014). CONCLUSION: This study indicated that a VAT score with a cut off of ≥8 had better phlebotomy and procedural outcomes in DDP collections and that donor with at least one arm having the VAT score of ≥8 are preferred for DDP collections.
Assuntos
Remoção de Componentes Sanguíneos/métodos , Plaquetas/citologia , Plaquetoferese/instrumentação , Plaquetoferese/métodos , Veias/anatomia & histologia , Veias/fisiologia , Adulto , Transfusão de Componentes Sanguíneos/instrumentação , Transfusão de Componentes Sanguíneos/métodos , Doadores de Sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Razão de Chances , Flebotomia , Estudos Prospectivos , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND: Patients can form antibodies to foreign human leukocyte antigen (HLA) Class I antigens after exposure to allogeneic cells. These anti-HLA class I antibodies can bind transfused platelets (PLTs) and mediate their destruction, thus leading to PLT refractoriness. Patients with PLT refractoriness need HLA-matched PLTs, which require expensive HLA typing of donors, antibody analyses of patient sera and/or crossmatching. An alternative approach is to reduce PLT HLA Class I expression using a brief incubation in citric acid on ice at low pH. METHODS AND MATERIALS: Apheresis PLT concentrates were depleted of HLA Class I complexes by 5 minutes incubation in ice-cold citric acid, at pH 3.0. Surface expression of HLA Class I complexes, CD62P, CD63, phosphatidylserine, and complement factor C3c was analyzed by flow cytometry. PLT functionality was tested by thromboelastography (TEG). RESULTS: Acid treatment reduced the expression of HLA Class I complexes by 71% and potential for C3c binding by 11.5-fold compared to untreated PLTs. Acid-treated PLTs were significantly more activated than untreated PLTs, but irrespective of this increase in steady-state activation, CD62P and CD63 were strongly upregulated on both acid-treated and untreated PLTs after stimulation with thrombin receptor agonist peptide. Acid treatment did not induce apoptosis over time. X-ray irradiation did not significantly influence the expression of HLA Class I complexes, CD62P, CD63, and TEG variables on acid treated PLTs. CONCLUSION: The relatively simple acid stripping method can be used with irradiated apheresis PLTs and may prevent transfusion-associated HLA sensitization and overcome PLT refractoriness.
Assuntos
Ácido Cítrico/efeitos adversos , Antígenos de Histocompatibilidade Classe I/efeitos dos fármacos , Transfusão de Plaquetas/métodos , Imunodeficiência Combinada Severa/induzido quimicamente , Anticorpos/imunologia , Tipagem e Reações Cruzadas Sanguíneas/métodos , Plaquetas/efeitos da radiação , Feminino , Antígenos de Histocompatibilidade Classe I/imunologia , Antígenos de Histocompatibilidade Classe I/metabolismo , Antígenos de Histocompatibilidade Classe I/efeitos da radiação , Teste de Histocompatibilidade/economia , Teste de Histocompatibilidade/métodos , Humanos , Selectina-P/metabolismo , Transfusão de Plaquetas/efeitos adversos , Plaquetoferese/métodos , Tetraspanina 30/metabolismo , Tromboelastografia/métodos , Trombocitopenia/terapia , Regulação para Cima/genéticaRESUMO
Due to circumstances such as increased demand and an aging donor pool, the likelihood of critical platelet shortages is increasing. The platelet supply could be improved through the expansion of the donor pool, the identification and sustained utilization of high-quality donors, and changes in component processing and storage that result in a longer platelet shelf-life. Refrigerated platelets, stored at 1° to 6°C, have the potential to improve patient safety by decreasing the risk of bacterial contamination while concurrently allowing for a longer storage period (eg, 14 days) and improved hemostatic effectiveness in actively bleeding patients. An approach utilizing remuneration of apheresis platelet donors combined with pathogen reduction of the platelet components could be used as a means to increase the donor pool and identify and sustain safe, reliable, high-quality donors. Remuneration might provide an incentive for underutilized populations (eg, individuals <30 years old) to enter the apheresis platelet donor population resulting in a significant expansion of the platelet donor pool. Over time, approaches such as the use of refrigerated platelets, platelet donor remuneration, and the application of pathogen reduction technology, might serve to attract a large, reliable, and safe donor base that provides platelet collections with high yields, longer shelf-lives and, excellent hemostatic function.
Assuntos
Plaquetas/citologia , Segurança do Sangue/normas , Transfusão de Plaquetas/estatística & dados numéricos , Doadores de Tecidos/provisão & distribuição , Adulto , Idoso , Preservação de Sangue/métodos , Preservação de Sangue/normas , Segurança do Sangue/estatística & dados numéricos , Criopreservação/métodos , Criopreservação/normas , Desinfecção/métodos , Desinfecção/normas , Humanos , Pessoa de Meia-Idade , Segurança do Paciente , Plaquetoferese/economia , Plaquetoferese/métodos , Remuneração , Tecnologia/métodos , Doadores de Tecidos/estatística & dados numéricosRESUMO
INTRODUCTION: Algorithms have been developed to predict the platelet yield after apheresis from the donor's data, as well as the effect on the blood cell count, to extract an acceptable platelet number without affecting the donor. However, the evaluation of these algorithms has not been widely reported. This study aimed to assess the accuracy of the predictive algorithms of the Trima Accel v. 6 blood collection system. METHODS: Platelet concentrates (PCs) obtained by apheresis were analyzed. Platelet count and hematocrit were compared pre- and post-apheresis. Calculated post-apheresis platelet count (CPAPC), hematocrit (CPAH), and platelet yield (CPY), and their actual values were correlated. The bias of the algorithms was assessed with Bland-Altman plots, and the prediction of the extraction of single or double platelet products was evaluated. RESULTS: Two hundred and seventy-nine PCs were analyzed. Post-apheresis platelet count (PAPC) and hematocrit were decreased. A moderate correlation was observed between CPY and the actual yield, with a negative bias, and a trend to increase alongside the magnitude of the measurements. CPAPC and CPAH were strongly correlated with their actual values without bias. Prediction of single or double platelet product extraction showed a significant agreement with the actual outcomes. CONCLUSIONS: The predictive algorithm for the platelet yield showed bias, and a trend to underestimate the actual platelet yields when they are higher. The algorithms for the prediction of the PAPC and hematocrit did not show bias, proving their accuracy. Prediction of a single or double platelet product extraction has a strong agreement with the APY.
Assuntos
Plaquetoferese/métodos , Adulto , Algoritmos , Feminino , Humanos , Masculino , Contagem de Plaquetas , SoftwareRESUMO
BACKGROUND: Effective and financially viable mitigation approaches are needed to reduce bacterial contamination of platelets in the US. Expected costs of large-volume delayed sampling (LVDS), which would be performed by a blood center prior to shipment to a hospital, were compared to those of pathogen reduction (PR), point-of-release testing (PORt), and secondary bacterial culture (SBC). METHODS: Using a Markov-based decision-tree model, the financial and clinical impact of implementing all variants of LVDS, PR, PORt, and SBC described in FDA guidance were evaluated from a hospital perspective. Hospitals were assumed to acquire leukoreduced apheresis platelets, with LVDS adding $30 per unit. Monte Carlo simulations were run to estimate the direct medical costs for platelet acquisition, testing, transfusion, and possible complications associated with each approach. Input parameters, including test sensitivity and specificity, were drawn from existing literature and costs (2018US$) were based on a hospital perspective. A one-way sensitivity analysis varied the assumed additional cost of LVDS. RESULTS: Under an approach of LVDS (7-day), the total cost per transfused unit is $735.78, which falls between estimates for SBC (7-day) and PORt. Assuming 20,000 transfusions each year, LVDS would cost $14.72 million annually. Per-unit LVDS costs would need to be less than $22.32 to be cheaper per transfusion than all other strategies, less than $32.02 to be cheaper than SBC (7-day), and less than $196.19 to be cheaper than PR (5-day). CONCLUSIONS: LVDS is an effective and cost-competitive approach, assuming additional costs to blood centers and associated charges to hospitals are modest.
Assuntos
Infecções Bacterianas/prevenção & controle , Contaminação de Medicamentos/prevenção & controle , Controle de Infecções , Transfusão de Plaquetas/economia , Transfusão de Plaquetas/estatística & dados numéricos , Plaquetoferese , Cultura Primária de Células/economia , Infecções Bacterianas/economia , Infecções Bacterianas/epidemiologia , Infecções Bacterianas/transmissão , Bancos de Sangue/economia , Bancos de Sangue/normas , Bancos de Sangue/estatística & dados numéricos , Plaquetas/microbiologia , Segurança do Sangue/economia , Segurança do Sangue/métodos , Segurança do Sangue/normas , Coleta de Amostras Sanguíneas/efeitos adversos , Coleta de Amostras Sanguíneas/economia , Coleta de Amostras Sanguíneas/normas , Coleta de Amostras Sanguíneas/estatística & dados numéricos , Custos e Análise de Custo , Testes Diagnósticos de Rotina/economia , Testes Diagnósticos de Rotina/normas , Testes Diagnósticos de Rotina/estatística & dados numéricos , Contaminação de Medicamentos/economia , Contaminação de Medicamentos/estatística & dados numéricos , Estudos de Viabilidade , Humanos , Ciência da Implementação , Controle de Infecções/economia , Controle de Infecções/métodos , Técnicas Microbiológicas , Plaquetoferese/efeitos adversos , Plaquetoferese/economia , Plaquetoferese/métodos , Plaquetoferese/normas , Cultura Primária de Células/métodos , Cultura Primária de Células/normas , Cultura Primária de Células/estatística & dados numéricos , Comportamento de Redução do Risco , Tamanho da Amostra , Fatores de Tempo , Tempo para o Tratamento/economia , Tempo para o Tratamento/estatística & dados numéricos , Reação Transfusional/economia , Reação Transfusional/epidemiologia , Reação Transfusional/microbiologia , Reação Transfusional/prevenção & controleRESUMO
Since there is still debate on the effects of plateletpheresis on coagulation system, we aimed to perform a global assessment of donor's hemostatic function undergoing plateletpheresis by rotation thromboelastometry (ROTEM) analysis and to clarify if plateletpheresis procedure induces a hypercoagulable state. Thirty male plateletpheresis donors were included in the study. Four blood samples were drawn at different time intervals: before the beginning of the apheresis procedure; immediately after the completion of the apheresis procedure; 24 h and 7 days after the apheresis procedure. "Hypercoagulability" was diagnosed readily by having an accelerated clot formation, as evidenced by shortening of CFT and an increase of the clot strength, as evidenced by increasing of MCF. In INTEM assay, CFT value after apheresis was significantly prolonged compared with baseline value while CFT value 7 days after apheresis was significantly shortened compared with values immediately and 24 h after apheresis (p < 0.001). However, CFT-INTEM still did not show any shortening in any of the measurements when compared to pre-apheresis value. MCF value after apheresis was significantly shortened compared with baseline value while MCF value 7 days after apheresis was significantly prolonged compared with values immediately and 24 h after apheresis (p < 0.001). However, MCF-INTEM still did not show any increase in any of the measurements when compared to pre-apheresis value. There was no significant difference in CT value between four measurements (p = 0.064). In EXTEM assay, CFT value after apheresis was significantly prolonged compared with baseline value while CFT value 7 days after apheresis was significantly shortened compared with values immediately and 24 h after apheresis (p < 0.001). However, CFT-EXTEM still did not show any shortening in any of the measurements when compared to pre-apheresis value. MCF values immediately and 24 h after apheresis were significantly shortened compared with baseline value while MCF value 7 days after apheresis was significantly prolonged compared with values immediately and 24 h after apheresis (p < 0.001). However, MCF-EXTEM still did not show any increase in any of the measurements when compared to pre-apheresis value. We found no differences in CT value between four measurements (p = 0.208). Since ROTEM tracings on both INTEM and EXTEM assays did not reveal any significant shortening of CFT and increasing of MCF in any of the measurements after apheresis procedure, we concluded that plateletpheresis does not induce a hypercoagulable state in healthy donors.
Assuntos
Plaquetoferese/métodos , Adolescente , Adulto , Idoso , Humanos , Masculino , Pessoa de Meia-Idade , Trombofilia , Doadores de Tecidos , Adulto JovemRESUMO
Platelet transfusions may be associated with certain adverse effects in recipients, potentially caused by the presence of biological response modifiers contained in the platelet concentrates. The aim of this study is to identify the parameters that reflect platelet activation during both the preparation process and the storage of platelet concentrates. A total of 3,949apheresis platelet concentrate samples were studied with regard to parameters related to the donor as well as to the preparation process and their storage. Key glycoproteins characteristic of platelet activation, i.e. soluble CD40L and CD62P, were quantified in platelet concentrate supernatants on completion of their processing and during storage, using Luminex technology. We observed an increase in soluble factors over time. However, the different parameters studied in connection either with the donors or with the donations, such as (i) donor gender, (ii) donor blood group, (iii) time of collection and (iv) type of apheresis separator, do not seem to have any effect on platelet activation or the release of soluble CD40L and CD62P.
Assuntos
Plaquetas , Preservação de Sangue , Ligante de CD40/análise , Selectina-P/análise , Ativação Plaquetária , Transfusão de Plaquetas , Plaquetoferese , Doadores de Sangue , Plaquetas/metabolismo , Ligante de CD40/biossíntese , Feminino , Humanos , Masculino , Selectina-P/biossíntese , Fatores de TempoRESUMO
BACKGROUND: Transfusion of washed platelet concentrates (W-PC) is recommended for some patients, such as those who have had previous severe allergic transfusion reactions. However, we still lack a standardised method for preparing these products. Here, we assessed the effect of a manual washing procedure on in vitro platelet quality and on the transfusion efficacy of W-PCs. MATERIALS AND METHODS: Buffy coat-derived W-PC in Composol solution were prepared by one-step centrifugation. Platelet activation and function were evaluated before and after washing by means of: (i) CD62 expression by flow cytometry; (ii) platelet aggregation (LTA); and (iii) the VerifyNow® P2Y12 test. A pilot prospective transfusion study was carried out in 11 onco-hematology patients receiving, in a short time, two consecutive transfusions: one with standard PC (S-PC) and one with W-PC. The post-transfusion platelet increment, the 1 h and 24 h corrected count increment (CCI) and occurrence of bleeding events were used as indices of transfusion efficacy. RESULTS: Platelet recovery in W-PC was 84.8±5.4%. Washing slightly increased platelet activation in W-PC vs pre-washed samples (% CD62+ platelets 23.6±7 vs 14.8±1; p=0.03). As compared to prewash samples, platelet reactivity of W-PC as measured by VerifyNow® P2Y12 was significantly lower with ADP (PRU 32.2±37.7 vs 4.2±2.4, p=0.027), but similar using TRAP. Platelet aggregation responses to TRAP, collagen, ristocetin and arachidonic acid were maintained in W-PC. The pilot transfusion trial showed similar 1 h (13.5±5.6 vs 11.5±7.3, p=0.49) and 24 h (11±7.2 vs 9±6.5, p=0.48) CCI for S-PC and W-PC. Transfusion of W-PC was not associated with an increased number of bleeding events. DISCUSSION: We have set up a simple method to obtain buffy-coat-derived W-PC, which has minor effects on in vitro platelet quality and transfusion effectiveness. This procedure can be easily implemented in transfusion centres for on-demand preparation of washed platelets.
Assuntos
Buffy Coat , Transfusão de Plaquetas/métodos , Plaquetoferese/métodos , Garantia da Qualidade dos Cuidados de Saúde , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos PilotoRESUMO
BACKGROUND: Pathogen inactivation (PI) is a new approach to blood safety that may introduce additional costs. This study identifies costs that could be eliminated, thereby mitigating the financial impact. STUDY DESIGN AND METHODS: Cost information was obtained from five institutions on tests and procedures (e.g., irradiation) currently performed, that could be eliminated. The impact of increased platelet (PLT) availability due to fewer testing losses, earlier entry into inventory, and fewer outdates with a 7-day shelf life were also estimated. Additional estimates include costs associated with managing (1) special requests and (2) test results, (3) quality control and proficiency testing, (4) equipment acquisition and maintenance, (5) replacement of units lost to positive tests, (6) seasonal or geographic testing, and (7) health department interactions. RESULTS: All costs are mean values per apheresis PLT unit in USD ($/unit). The estimated test costs that could be eliminated are $71.76/unit and a decrease in transfusion reactions corresponds to $2.70/unit. Avoiding new tests (e.g., Babesia and dengue) amounts to $41.80/unit. Elimination of irradiation saves $8.50/unit, while decreased outdating with 7-day storage can be amortized to $16.89/unit. Total potential costs saved with PI is $141.65/unit. Costs are influenced by a variety of factors specific to institutions such as testing practices and the location in which such costs are incurred and careful analysis should be performed. Additional benefits, not quantified, include retention of some currently deferred donors and scheduling flexibility due to 7-day storage. CONCLUSIONS: While PI implementation will result in additional costs, there are also potential offsetting cost reductions, especially after 7-day storage licensing.
Assuntos
Plaquetas , Preservação de Sangue/economia , Segurança do Sangue/economia , Desinfecção/economia , Plaquetoferese/economia , Preservação de Sangue/métodos , Segurança do Sangue/métodos , Custos e Análise de Custo , Desinfecção/métodos , Humanos , Plaquetoferese/métodosRESUMO
Storage impairs platelet function. It was hypothesized that multiple electrode aggregometry in vitro could be used to follow aggregability in platelet concentrates over time and that the results predict the efficacy of platelet transfusion in an ex vivo transfusion model. In vitro platelet aggregability was assessed in apheresis and pooled buffy coat platelet concentrates (BCs) (n = 13 each) using multiple electrode aggregometry with different agonists 1, 3, 5 and 7 days after preparation. In the ex vivo transfusion model, whole blood samples from nine healthy volunteers were collected every second day. The samples were supplemented with stored platelets (+146 × 10(9) × l(-1)) from the same unit 1, 3, 5 and 7 days after preparation. Platelet aggregability was assessed in the concentrate and in the whole blood samples before and after platelet supplementation. There was a continuous reduction in in vitro platelet aggregability over time in both apheresis and pooled BCs. The same pattern was observed after ex vivo addition of apheresis and pooled BCs to whole blood samples. The best correlation between in vitro aggregability and changes in aggregation after addition was achieved with collagen as agonist (r = 0.67, p < 0.001). In conclusion, multiple electrode aggregometry can be used to follow aggregability in platelet concentrates in vitro, and the results predict with moderate accuracy changes in aggregation after addition of platelet concentrate to whole blood samples.
Assuntos
Eletrodos , Técnicas In Vitro , Agregação Plaquetária , Testes de Função Plaquetária/métodos , Preservação de Sangue/métodos , Humanos , Testes de Função Plaquetária/instrumentação , Transfusão de Plaquetas , Plaquetoferese , Fatores de TempoRESUMO
In developing countries, like Indonesia, apheresis is still a relative new procedure. Nowadays, therapeutic apheresis procedures are performed in the field of hematology and neurology, especially in the teaching hospitals in Indonesia. Therapeutic apheresis procedure, that is, leukocytapheresis, therapeutic plasma exchange (TPE), and thrombocytapheresis are already performed. In the period 2009-2013, 204 apheresis procedures in 137 patients to reduce the leukocytes, 72 TPE procedures in 17 patients, and 14 thrombocyte reductions were performed in the Sardjito hospital, Yogyakarta, Indonesia. In the future, to improve the therapeutic apheresis implementation, it is important to increase the insurance coverage and also should be considered to introduce the apheresis medicine into the curriculum of appropriate physician programs in Indonesia. Especially in Indonesia, a lot of efforts are still being needed to improve implementation of therapeutic apheresis.
Assuntos
Troca Plasmática/métodos , Plasmaferese/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Ásia , Plaquetas/citologia , Humanos , Indonésia , Seguro Saúde , Leucemia Mielogênica Crônica BCR-ABL Positiva/sangue , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Leucócitos/citologia , Pessoa de Meia-Idade , Plaquetoferese , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Adulto JovemRESUMO
Trehalose is widely used as a cryoprotective reagent to preserve various cells. Platelet additive solution-III (PAS) has been used to maintain platelet function, benefit the virus inactivation, and extend the storage period. PAS with trehalose (PAS-III M + T) may effectively protect platelets (PLTs) at a relatively low temperature (10 °C). The apheresis PLTs from six donors were divided into two groups. Group A was stored in PAS-III M + T at 10 °C as experimental group and group B in plasma at 22 °C as control group. The samples were collected on different storage dates, and multiple parameters were determined or investigated for in vitro studies. The in vivo recovery and survival of rabbit PLTs stored in the same conditions, and then labeled with (51)Cr were measured and evaluated using a rabbit model of thrombocytopenia. Over 9 days, P-selectin expression increased significantly in a time-dependent manner in both groups (n = 6). The levels of the hypotonic shock reaction and PLT aggregation rate decreased in both groups and were significantly higher in group A than B after 1 day of storage. The lactate dehydrogenase (LDH) release and glucose (GLU) consumption increased similarly, but the levels were significantly lower in group A than B. The pH decreased significantly after 5 days of storage in group B but did not change in group A. After 5 days, the morphology of the PLTs in group B maintained a more normal shape than that of group A. The recovery and survival of PLTs stored in both groups were not significantly different (p > 0.05). The bacteria growth was not examined out in both groups for up to 5 (group A) and 9 (group B) days. Storage of PLTs in the modified PAS at low temperature was more effective in protecting PLT functions than that of standard storage method and may have the potential to decrease the risk of PLT activation and bacterial contamination.
Assuntos
Plaquetas , Preservação de Sangue/métodos , Preservação de Sangue/normas , Transfusão de Plaquetas , Trombocitopenia/sangue , Trombocitopenia/terapia , Animais , Plaquetas/metabolismo , Plaquetas/ultraestrutura , Modelos Animais de Doenças , Humanos , Plaquetoferese/métodos , Plaquetoferese/normas , Garantia da Qualidade dos Cuidados de Saúde , Coelhos , Temperatura , Trombocitopenia/mortalidade , Resultado do Tratamento , Trealose/farmacologiaRESUMO
BACKGROUND: The primary goals of apheresis platelet (AP) inventory management are to meet demand and minimize waste. AP inventory management is complicated by unpredictable demand for a product with a shelf life of only a few days and by hospital requests for APs that match the ABO types of patients identically. STUDY DESIGN AND METHODS: A simulation-based decision support system was developed to assist blood centers in reducing waste while meeting the demand for ABO-identical APs. The proposed model is validated using data from a blood center located in a major city in the southeast region of the United States. RESULTS: Based on data provided by the blood center, the proposed simulation model is able to suggest appropriate collection strategies that can reduce AP waste from 12%-14% to 6%-7% and decrease the unmet demand for ABO-identical APs from 25% to 21%. CONCLUSION: The proposed simulation-based decision-making model is able to mimic the complexity of the AP inventory management system while reducing waste and predicting the need for ABO-identical APs.
Assuntos
Bancos de Sangue/organização & administração , Remoção de Componentes Sanguíneos/estatística & dados numéricos , Simulação por Computador , Necessidades e Demandas de Serviços de Saúde , Inventários Hospitalares/organização & administração , Transfusão de Plaquetas/estatística & dados numéricos , Eficiência Organizacional , Humanos , Inventários Hospitalares/normas , Avaliação de Processos e Resultados em Cuidados de Saúde/métodos , Plaquetoferese/estatística & dados numéricos , Reprodutibilidade dos Testes , SoftwareRESUMO
BACKGROUND: Pathogen inactivation (PI) technology for blood components enhances blood safety by inactivating viruses, bacteria, parasites, and white blood cells. Additionally, PI for platelet (PLT) components has the potential to extend PLT storage time from 5 to 7 days. STUDY DESIGN AND METHODS: A retrospective analysis was conducted into the percentage of outdated PLT components during the 3 years before and after the adoption of PLT PI technology in our institution. The PLT transfusion dose for both pre-PI and post-PI periods was similar. A retrospective analysis to study clinical safety and component utilization was also performed in the Balearic Islands University Hospital. RESULTS: As a result of PI implementation in our institution, the PLT production cost increased by 85.5%. However, due to the extension of PLT storage time, the percentage of outdated PLT units substantially decreased (-83.9%) and, consequently, the cost associated with outdated units (-69.8%). This decrease represented a 13.7% reduction of the initial cost increase which, together with the saving in blood transportation (0.1%), led to a saving of 13.8% over the initial cost. Therefore, the initial 85.5% increase in the cost of PLT production was markedly reduced to 71.7%. The mean number of PLT concentrates per patient was similar during both periods. CONCLUSIONS: The extension of PLT storage time can substantially contribute to reducing the financial impact of PI by decreasing the percentage of outdated PLTs while improving blood safety. Since the adoption of PI, there have been no documented cases of PLT transfusion-related sepsis in our region.
Assuntos
Plaquetas/microbiologia , Segurança do Sangue/economia , Segurança do Sangue/métodos , Patógenos Transmitidos pelo Sangue , Viabilidade Microbiana , Segurança do Sangue/estatística & dados numéricos , Redução de Custos/métodos , Feminino , Hospitais Universitários , Humanos , Masculino , Pessoa de Meia-Idade , Transfusão de Plaquetas/efeitos adversos , Transfusão de Plaquetas/métodos , Transfusão de Plaquetas/normas , Plaquetoferese/normas , Plaquetoferese/estatística & dados numéricos , Estudos Retrospectivos , Espanha/epidemiologiaRESUMO
BACKGROUND AND OBJECTIVES: Buffy-coat (BC)-derived platelet concentrates (PCs) are the predominant product for platelet transfusion in many countries. Two automated systems, OrbiSac and TACSI, have been introduced in blood centres to prepare these PCs, as an alternative to the manual method. We compared the in vitro quality of PCs prepared by both methods during standard storage. STUDY DESIGN AND METHODS: Twenty primary BC pools were split into two parts, which were processed with OrbiSac and TACSI system to obtain OrbiSac PCs (O-PCs) and TACSI PCs (T-PCs), respectively. On days 1, 5 and 7 of standard storage, samples were taken and the following analysed: cell count, metabolic variables, platelet function and content of activation and proinflammatory substances. RESULTS: Both the OrbiSac and TACSI systems produced PCs that meet the standards for platelet products in terms of platelet and leucocyte content. In vitro evaluation pointed to the similar preservation of platelet metabolism (pH, glucose, bicarbonate and lactate) in O-PCs and T-PCs. Moreover, there were no significant differences between O-PCs and T-PCs as regards the hypotonic shock response or in the platelet aggregation profile. The OrbiSac system caused greater platelet activation, which resulted in higher concentrations of sCD62P, RANTES and sCD40L on the day the PCs were prepared. CONCLUSION: The systems OrbiSac and TACSI can be used to produce buffy-coat-derived PCs whose cell content, platelet function and metabolism are similar during standard storage. However, the preparation with the OrbiSac system induces a transient increase in platelet activation and release of proinflammatory substances.
Assuntos
Buffy Coat/citologia , Plaquetas/citologia , Plasma/citologia , Plaquetoferese/instrumentação , Buffy Coat/fisiologia , Plaquetas/fisiologia , Humanos , Procedimentos de Redução de Leucócitos , Plasma/química , Ativação Plaquetária , Agregação Plaquetária , Testes de Função Plaquetária , Transfusão de PlaquetasRESUMO
The demand for human monocyte-derived dendritic cells (moDCs), as well as for primary human B and T lymphocytes for immunological research purposes has been increased in recent years. Classically, these monocytes are isolated from blood, leukapheresis products or buffy coats of healthy donors by plastic adherence of peripheral blood mononuclear cells (PBMCs), followed by stimulation with granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4, while lymphocytes are usually isolated from the non-adherent fraction (NAF) by magnetic cell sorting. However, donor-blood is a limited resource and not every blood bank offers leukapheresis products or buffy coats for laboratory use. Additionally, a leukapheresis is very expensive and also the generation/isolation of cells is time- and cost-intensive. To overcome some of these obstacles, we evaluated if low-cost leukoreduction system chambers (LRSCs), which arise after routine donor plateletpheresis procedures, and are usually discarded, would be an alternative and appropriate source of PBMCs to generate moDCs and to isolate lymphocytes. By analyzing the number and phenotype of immature and mature dendritic cells (DCs), as well as of B and T lymphocytes derived from LRSCs, we found all cells to be of high quantity and quality. Further investigations on DCs comprising transwell migration assays, allogeneic mixed lymphocyte reactions (MLR), cytokine secretion assays, and cytotoxic T cell induction assays revealed high migratory, as well as stimulatory capacity of these cells. In addition, DCs and T cells were efficiently electroporated with mRNA and showed characteristic cytokine production after co-culture, demonstrating LRSCs as an efficient, valid, and economic source for generation of moDCs and lymphocytes for research purposes.
Assuntos
Linfócitos T CD4-Positivos/citologia , Linfócitos T CD8-Positivos/citologia , Células Dendríticas/citologia , Leucócitos Mononucleares/citologia , Plaquetoferese/métodos , Técnicas de Cultura de Células , Proliferação de Células , Células Cultivadas , Criopreservação , Citometria de Fluxo , Fator Estimulador de Colônias de Granulócitos e Macrófagos/metabolismo , Humanos , Interleucina-4/metabolismoRESUMO
BACKGROUND: Good blood banking practice requires that every effort should be made to detect any deviation or defect in blood bank products and to identify any potential risk to blood donor or recipient(s). We report the findings of an exercise that provide an insight into why feedback from the user side is crucial. STUDY DESIGN AND METHODS: Various events involving blood bags and plateletpheresis kits and the corresponding appropriate actions instituted for remedial measures were recorded. These scattered events were recorded for 6 months following the use of a new batch of improved blood bags with add-on features. Several events related to plateletpheresis kits from three different manufacturers were also recorded for 1 year. RESULTS: The affected blood bags were utilized with no untoward incident. The complaint was closed following satisfactory response from the blood bag manufacturing company that acted in a timely manner in addressing the root causes of the problems. However, corrective and preventive actions (CAPA) could not be implemented for plateletpheresis kits. The rate of undesirable events was higher with plateletpheresis kits as compared with whole blood bags (1.75% vs. 0.06%). CONCLUSION: As defects or deviations that trigger the need for CAPA can stem from numerous sources, it is important to clearly identify and document the problems and level of risk so that appropriate investigations can be instituted and remedial actions can be taken in a timely manner. This study demonstrates the usefulness of a quality initiative to collate and analyze blood product faults in conjunction with blood product manufacturers.
Assuntos
Bancos de Sangue/normas , Segurança do Sangue/instrumentação , Coleta de Amostras Sanguíneas/instrumentação , Falha de Equipamento/estatística & dados numéricos , Necessidades e Demandas de Serviços de Saúde , Plaquetoferese/instrumentação , Acidentes de Trabalho/prevenção & controle , Acidentes de Trabalho/estatística & dados numéricos , Algoritmos , Bancos de Sangue/legislação & jurisprudência , Bancos de Sangue/organização & administração , Bancos de Sangue/estatística & dados numéricos , Segurança do Sangue/métodos , Segurança do Sangue/normas , Coleta de Amostras Sanguíneas/normas , Coleta de Amostras Sanguíneas/estatística & dados numéricos , Necessidades e Demandas de Serviços de Saúde/normas , Humanos , Saúde Ocupacional/normas , Plaquetoferese/métodos , Plaquetoferese/normas , Plaquetoferese/estatística & dados numéricos , Prática Profissional/normas , Prática Profissional/estatística & dados numéricos , Melhoria de Qualidade , Kit de Reagentes para Diagnóstico/normas , Gestão de Riscos , Fatores de TempoRESUMO
Platelet concentrates (PCs) prepared either from whole-blood donations by the buffy-coat method (BC), or by plateletpheresis are indicated to prevent or treat acute hemorrhage secondary to thrombocytopenia, and there is an ongoing debate about which platelet product should be used. Usage of each of these two products is highly heterogeneous among countries and individual institutions, ranging from 10 to 90%, with a 50:50 ratio in Europe. In comparison of pooled platelets prepared by the BC method and apheresis PCs, data suggest similar efficacy of the products. Regarding recipients' adverse reactions, there is no advantage for apheresis concentrates. From the donor's point of view, evidence favours using the abundance of platelets available from whole-blood donation. As residual viral transmission risk continues to fall, the advantage of apheresis products related to the decrease to donor exposure lessens. While the cost-effectiveness of apheresis products is comparable to that of other accepted blood safety interventions, in case of emerging pathogens, probably pathogen inactivation of pooled BC PCs would be a more desirable strategy.
Assuntos
Buffy Coat , Doadores de Sangue , Transfusão de Plaquetas , Plaquetoferese , Segurança do Sangue , Análise Custo-Benefício , Humanos , Transfusão de Plaquetas/efeitos adversos , Transfusão de Plaquetas/economia , Plaquetoferese/efeitos adversos , Plaquetoferese/economia , EspanhaRESUMO
BACKGROUND: Blood component donations by apheresis has become more common in modern blood transfusion practices. However, apheresis donation still remains less common in China. This study describes the demographic profile and transfusion-transmissible infection (TTI) prevalence among donors making apheresis platelet (AP) donations compared to those making whole blood (WB) donations and the differences among five geographically diverse blood centers in China. STUDY DESIGN AND METHODS: This is a descriptive study using data from all successful donations at the five blood centers in 2008 and 2009. Donor demographic and TTI screening reactive rates were collected for WB and AP donations and blood centers. Logistic regression was used to identify independent factors associated with AP donations. RESULTS: From January 1, 2008, to December 31, 2009, there were 512,594 WB and 26,199 AP donations at five blood centers. AP donations accounted for 4.9% of all donations. AP donations have lower reactive rate than WB donations for hepatitis B virus surface antigen, hepatitis C virus antibodies, human immunodeficiency virus antibodies, and syphilis screening testing. Males, donors older than 25 years old, non-Han donors, and donors with below high school educational level were more likely to make AP donations. The characteristics of AP donations differed among the five Chinese blood centers. CONCLUSION: Our analysis suggests that the characteristics of AP donations in China are different from WB donations and differ among the five Chinese blood centers. Some of the differences are likely due to different recruitment policies. Further studies should be conducted to understand what motivates Chinese blood donors to participate as AP donors.